b.1.351
Vaccineexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05124171)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05518487 | Phase 2 | Nov 10, 2022 | Icahn School of Medicine at Mount Sinai, Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), PPD, Sanofi-Aventis |
| NCT05405283 | Phase 3 | Jun 8, 2022 | Assistance Publique - Hôpitaux de Paris, COVIREIVAC |
| NCT05289037 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2022 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05029856 | Phase 1/Phase 2 (Phase 2) | Feb 4, 2022 | Novavax |
| NCT05124171 | Phase 3 | Nov 30, 2021 | Assistance Publique - Hôpitaux de Paris, COVIREIVAC |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 2 | 2 | 1 | 2021 |
| COVIREIVAC | Academic/Hospital | 2 | 0 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2022 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Novavax | For profit | 1 | 1 | 1 | 2022 |
| PPD | For profit | 1 | 0 | 1 | 2022 |
| Sanofi-Aventis | For profit | 1 | 0 | 1 | 2022 |
8 organizations
Page 1 / 1